Company Number: 14163582

Analysis Date: 2025-07-29 20:07 UTC

1. Credit Opinion: DECLINE

ROQ PHARMA LIMITED is a newly incorporated micro-entity (since 2022) with minimal financial activity and disclosures. The company’s financial statements show nominal current assets and net assets of only £100 consistently over the last three years, with zero employees and no indication of operating revenue or profit. Such limited financial scale and operational data provide insufficient evidence of the company’s ability to generate cash flow or service any debt obligation. The stagnant balance sheet with no growth or substantive assets suggests a lack of trading activity and business substance, which raises concerns about the company’s resilience and management effectiveness from a credit perspective.

2. Financial Strength:

The company’s balance sheet is extremely weak and minimalistic, showing total net assets of only £100 and current assets of £100 with no liabilities. There are no fixed assets or other investments. The micro-entity classification and the absence of operating employees indicate a very small or dormant business with negligible financial strength. Shareholders’ funds remain constant at £100, implying no capital injections or retained earnings growth. This financial position does not support credit extension beyond very minimal unsecured facilities, if any.

3. Cash Flow Assessment:

No detailed cash flow information is provided, but the static and nominal current assets figure combined with zero employees strongly suggests no meaningful working capital or liquidity generation. The company lacks visible operational cash inflows and does not demonstrate the ability to manage working capital or meet short-term obligations beyond the trivial level of £100 assets. This severely limits the company’s capacity to service debt or fund growth internally.

4. Monitoring Points:

• Monitor any forthcoming financial filings for actual trading results or cash flow improvements.
• Watch for changes in directors or significant control that might indicate restructuring or new investment.
• Assess any upcoming credit applications for detailed business plans and financial forecasts.
• Evaluate any material changes in asset base or working capital that could improve creditworthiness.